Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT00116571 is registered in ClinicalTrials.gov with QLT Inc. as lead sponsor.

NCT NCT00116571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Lead sponsor
QLT Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2005
Completion date
December 31, 2006
Enrollment
180
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic hyperplasia